Neurogene Inc.’s Post

We are very proud to announce that we are a partner in the DNA Process Development & Manufacturing Summit Conference in #Boston on 5th, 6th and 7th of March. Julen Oyarzabal, CSO at Syngoi, will be at this important conference to talk about the process of optimising linear synthetic DNA. See you there? https://lnkd.in/d4sUhg5V #DNA #celltherapy #biotech #manufacturingDNA #chemicalbiology.

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Investors pour $370M+ into Ken Song's autoimmune biotech after his RayzeBio success: Ken Song knows how to step on the gas pedal. His new company, called Candid Therapeutics, emerged from stealth on Monday morning with more than $370 million to its name and two clinical-stage T cell engagers, a class that’s successful in oncology and could have a future in the bustling autoimmune field, much like cell therapies. The biotech exec launched the new startup less than a year after selling the late-stage radiopharma company RayzeBio to Bristol Myers Squibb for about $4.1 billion. Song took RayzeBio from Series A to IPO in three years and Nasdaq debut to M&A exit in about three months. Shortly after the RayzeBio deal closed in February, Song set up Candid as a shell company and started a hunt for clinical-stage drugs in oncology, pain, autoimmune and other areas, exploring nearly 50 opportunities. The emerging data on cell therapies in autoimmune diseases caught Song’s eye. Some cell therapy makers like Caribou Biosciences and Nkarta have either added autoimmune indications to their pipeline or shifted away from oncology, but Song felt there was another approach. T cell engagers could be easier for patients to take than cell therapies, and they also have a less complex manufacturing process and thus are easier to scale, he said. “To me, it was fairly obvious that an antibody-based approach, like with a T cell engager, could be the right solution,” Song said in an interview. He quickly lined up investors, who he said were willing to dish out even more than the $370 million that they finally landed on, and inked two acquisitions: Vignette Bio, and TRC 2004. Vignette came from Foresite Labs, and the somewhat stealth-stage TRC 2004 derives from Third Rock Ventures and Two River, which is run by Kite Pharma founder Arie Belldegrun. Vignette said last week it would pay $60 million upfront for a BCMAxCD3 bispecific from EpimAb Biotherapeutics, and it could eventually spend another $575 million in biobucks. And TRC 2004 broke cover last month with a “double-digit million” upfront, plus $443 million in milestones, for a CD20xCD3 bispecific antibody from Genor Biopharma. Candid also has a discovery effort looking at two new ideas for next-generation T cell engagers, Song said. Repurposing T cell engagers Candid said its two T cell engager antibodies — renamed CND106 and CND261 — have clinical data in more than 130 patients in various cancers, but are now being repositioned for autoimmune diseases. Amgen opened the field, and other drugmakers are following up with T cell engagers of their own, mostly for cancers. The company plans to put the two antibodies in the clinic early next year, Song said. Candid has already picked a set of lead indications, which… #lucidquest #genetherapy #celltherapy

Didn’t catch Lonza’s recent webinar: “Discover the Freshness of Frozen PBMCs – An Assessment of Cryopreservation Impact on T Cell Activation and Phenotype.” Aurita Menezes, PhD, Katherine Dunnick, PhD, and Sarah Thacker, PhD share what possible effects cryopreservation could have on the functionality of PBMC samples. Watch it on-demand, here: https://bit.ly/3VPDVI5 #Cryopreservation #TCell

If you’re developing antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), or other oligonucleotide variants, you know the promise these molecules have for transforming human health. Watch this short video presentation to learn how we can support you at every step of your oligonucleotide manufacturing journey. https://lnkd.in/dMThyxvk #oligos #oligonucleotides

I will be speaking on October 9th about the mission, and vision of CHCF with focus on early molecular diagnosis and curative treatment of brain conditions with life threatening behaviors (LTB). #NIH #Brain #NIMH #NINDS #NHGRI #biomarkers #diagnostics #CDRH #FDA #Biotech #neuroscience

Did you miss our webinar yesterday on advanced therapies?... Well you'll be in luck soon because we recorded it. What did we cover? -Cell therapies and the dynamics between distributed vs. bedside -AAV and the "normalization" of that field (and some deals)! -Oligos coming back into focus in a big way -Delivery delivery delivery Let us know what you think. And if you'll be in #Boston next week reach out and we can meet. #biotechnology #genetherapy

Assay turnaround time (TAT) is another critical factor in ensuring your lab has a targeted NGS solution available to assess key driver alterations. Pillar Biosciences Incorporated oncoReveal panels have a simple single-day NGS workflow enabling results reporting in as little as 2 days.

Enlivex (Nasdaq: $ENLV), a leader in macrophage reprogramming immunotherapy, has launched a brand new website! Discover their innovative Allocetra™ therapy, designed to reset macrophages and rebalance the immune system. Visit now to learn more: https://ow.ly/pey450SSmEK #macrophages #immunesystem #osteoarthritis #Biotechnology #biotech #stocks #stockmarket #nasdaq #StockMarketNews

In a recent investor webinar, our Executive Director, Thomas Duthy provided an in-depth breakdown of our recent Phase I/II Clinical Trial Results for Rett Syndrome. Watch the update below as he explains the findings. You can watch the full investor webinar here:  https://lnkd.in/gWntFZps #RettSyndrome #Retts #Biotech #NTI #Neurotech

Investor Update An interesting stock is 10x Genome (NSDQ:TXG). On Jul 10, Illumina Inc (NASDAQ:ILMN) acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration. Result - 10x Genome stocks have started trading lower. Why is this deal important? - Illumina Inc (NASDAQ:ILMN) acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration. In a crowded Single-Cell market, Cost reduction has become key consideration. Given that 10x Genome kits are used with Illumina NGS systems, this deal will encourage NGS platform to use Fluent's single cell prep kits. This can potentially reduce 10x revenues by 10%. Stock Price - Analysts have lowered target price to $26 - $29 (an upside of 47% - 56%) from current level. Source - MS News